Evidence map›Paper›PMID 30293119›Full record

ArticleJournal of cancer research and clinical oncology2018

Pre-treatment metabolic tumor volume predicts tumor metastasis and progression in high-grade salivary gland carcinoma.

Turki M Almuhaimid, Won Sub Lim, Jong-Lyel Roh, Jungsu S Oh, Jae Seung Kim, Soo-Jong Kim, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Diagnostic and Prognostic Utility ofAJR. American journal of roentgenology · 2021
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Turki M Almuhaimid *Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Won Sub Lim *Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Jong-Lyel RohDepartment of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. rohjl@amc.seoul.kr.ORCID http://orcid.org/0000-0002-1537-1977
Jungsu S OhDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jae Seung KimDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Soo-Jong KimDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Seung-Ho ChoiDepartment of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Soon Yuhl NamDepartment of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Sang Yoon KimDepartment of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Ulsan College · KR

Funding

National Research Foundation of Korea 2015R1A2A1A15054540
6 · The paper itself

Abstract

purposeHigh-grade salivary gland carcinoma (SGC) shows a high rate of metastasis and post-treatment recurrence, resulting in poor patient survival. Therefore, we evaluated the utility of pre-treatment

methodsThis observational study included 75 patients with previously untreated high-grade SGC who underwent pre-treatment

resultsA total of 36 (48%) patients had neck or distant metastases at initial staging. After controlling for clinical factors, MTV (> 8.8 mL) was an independent factor for initial metastasis (adjusted odds ratio 4.80, 95% confidence interval 1.09-21.20; P = 0.039). All PET parameters of SUV

conclusionsMTV is useful among quantitative PET measurements for predicting initial metastasis and PFS in patients with high-grade SGC.

Indexed as

AdolescentAdultAgedAged, 80 and overDisease ProgressionFemaleFluorodeoxyglucose F18HumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm GradingNeoplasm MetastasisNeoplasm StagingPositron Emission Tomography Computed TomographyPrognosisFluorodeoxyglucose F1818F-FDG PET/CTHigh-grade salivary gland cancerMetabolic tumor volumeMetastasisRisk factors

Identifiers

PMID30293119
PMCPMC11813259
OpenAlexW2895747839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.